These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19050056)

  • 1. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.
    Wesseling-Perry K; Pereira RC; Wang H; Elashoff RM; Sahney S; Gales B; Jüppner H; Salusky IB
    J Clin Endocrinol Metab; 2009 Feb; 94(2):511-7. PubMed ID: 19050056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The relationship between advancement of secondary hyperparathyroidism and selected calcification parameters in peritoneal dialysis patients].
    Janda K; Krzanowski M; Dumnicka P; Kuśnierz-Cabala B; Sułowicz W
    Przegl Lek; 2012; 69(12):1241-5. PubMed ID: 23750431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of FGF-23 measurement in dialysis patients.
    Jongbloed F; Galassi A; Cozzolino M; Zietse R; Chiarelli G; Cusi D; Brancaccio D; Gallieni M
    Clin Nephrol; 2011 Sep; 76(3):201-9. PubMed ID: 21888857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.
    Nakanishi S; Kazama JJ; Nii-Kono T; Omori K; Yamashita T; Fukumoto S; Gejyo F; Shigematsu T; Fukagawa M
    Kidney Int; 2005 Mar; 67(3):1171-8. PubMed ID: 15698459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysis.
    Lima F; El-Husseini A; Monier-Faugere MC; David V; Mawad H; Quarles D; Malluche HH
    Clin Nephrol; 2014 Nov; 82(5):287-95. PubMed ID: 25208316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?
    Wesseling-Perry K; Tsai EW; Ettenger RB; Jüppner H; Salusky IB
    Nephrol Dial Transplant; 2011 Nov; 26(11):3779-84. PubMed ID: 21441401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
    Shigematsu T; Kazama JJ; Yamashita T; Fukumoto S; Hosoya T; Gejyo F; Fukagawa M
    Am J Kidney Dis; 2004 Aug; 44(2):250-6. PubMed ID: 15264182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.
    Tanaka H; Hamano T; Fujii N; Tomida K; Matsui I; Mikami S; Nagasawa Y; Ito T; Moriyama T; Horio M; Imai E; Isaka Y; Rakugi H
    Bone; 2009 Nov; 45(5):949-55. PubMed ID: 19631779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower fibroblast growth factor 23 levels in young adults with Crohn disease as a possible secondary compensatory effect on the disturbance of bone and mineral metabolism.
    Oikonomou KA; Orfanidou TI; Vlychou MK; Kapsoritakis AN; Tsezou A; Malizos KN; Potamianos SP
    J Clin Densitom; 2014; 17(1):177-84. PubMed ID: 23623649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
    Evenepoel P; Meijers B; Viaene L; Bammens B; Claes K; Kuypers D; Vanderschueren D; Vanrenterghem Y
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.
    Tomida K; Hamano T; Mikami S; Fujii N; Okada N; Matsui I; Nagasawa Y; Moriyama T; Ito T; Imai E; Isaka Y; Rakugi H
    Bone; 2009 Apr; 44(4):678-83. PubMed ID: 19111635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD.
    Wetmore JB; Santos PW; Mahnken JD; Krebill R; Menard R; Gutta H; Quarles LD
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E57-64. PubMed ID: 20943782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84).
    Wesseling-Perry K; Harkins GC; Wang HJ; Elashoff R; Gales B; Horwitz MJ; Stewart AF; Jüppner H; Salusky IB
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2772-80. PubMed ID: 20382692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients.
    Park SY; Jeong KH; Moon JY; Lee SH; Ihm CG; Rhee SY; Woo JT; Oh IH; Lee TW
    Clin Exp Nephrol; 2010 Jun; 14(3):239-43. PubMed ID: 20376517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
    Navarro JF; Mora C; Macia M; Garcia J
    Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biological activity of FGF-23 and pathophysiologic role in chronic kidney disease].
    Yamashita T
    Clin Calcium; 2004 May; 14(5):760-3. PubMed ID: 15577039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.
    Sato T; Tominaga Y; Ueki T; Goto N; Matsuoka S; Katayama A; Haba T; Uchida K; Nakanishi S; Kazama JJ; Gejyo F; Yamashita T; Fukagawa M
    Am J Kidney Dis; 2004 Sep; 44(3):481-7. PubMed ID: 15332221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial differences in markers of mineral metabolism in advanced chronic kidney disease.
    Jovanovich A; Chonchol M; Cheung AK; Kaufman JS; Greene T; Roberts WL; Smits G; Kendrick J;
    Clin J Am Soc Nephrol; 2012 Apr; 7(4):640-7. PubMed ID: 22383748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.